{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:24:59Z","timestamp":1794050699058,"version":"4.8.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.meegid.2026.106041","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:58Z","timestamp":1791588418000},"page":"106041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An overview of current technologies in the development of drugs and vaccines against dengue virus"],"prefix":"10.1016","volume":"146","author":[{"given":"Masoud","family":"Pourzangiabadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morteza","family":"Barkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamideh","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Pouladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6299","key":"10.1016\/j.meegid.2026.106041_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.meegid.2026.106041_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005179","article-title":"The impact of the newly licensed dengue vaccine in endemic countries","volume":"10","author":"Aguiar","year":"2016","journal-title":"PLoS neglected tropical diseases"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0015","doi-asserted-by":"crossref","first-page":"13130","DOI":"10.1038\/s41598-024-63064-1","article-title":"In silico design of peptide inhibitors for Dengue virus to treat Dengue virus-associated infections","volume":"14","author":"Ajmal","year":"2024","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s43450-023-00510-7","article-title":"Antiviral Activity of Withanolide A Against Different Infectivity Phases of Dengue Virus Serotype 2 in Vero Cell Line","volume":"34","author":"Al Quwatli","year":"2024","journal-title":"Revista Brasileira de Farmacognosia"},{"key":"10.1016\/j.meegid.2026.106041_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.866452","article-title":"In vitro antiviral activity of potential medicinal plant extracts against dengue and chikungunya viruses","volume":"12","author":"Alagarasu","year":"2022","journal-title":"Frontiers in Cellular and Infection Microbiology"},{"key":"10.1016\/j.meegid.2026.106041_bb0030","first-page":"1","article-title":"Investigating the effects of four medicinal plants against dengue virus through QSAR modeling and molecular dynamics studies","author":"Alotaibi","year":"2024","journal-title":"Journal of Biomolecular Structure and Dynamics"},{"key":"10.1016\/j.meegid.2026.106041_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2023.102598","article-title":"Qdenga\u00ae \u2013 A promising dengue fever vaccine; can it be recommended to non-immune travelers?","volume":"54","author":"Angelin","year":"2023","journal-title":"Travel Medicine and Infectious Disease"},{"issue":"4","key":"10.1016\/j.meegid.2026.106041_bb0040","doi-asserted-by":"crossref","DOI":"10.5530\/pj.2020.12.124","article-title":"Drug of action cassia alata leaves extract as antiviral to dengue virus serotype-2 in vitro","volume":"12","author":"Angelina","year":"2020","journal-title":"Pharmacognosy Journal"},{"issue":"18","key":"10.1016\/j.meegid.2026.106041_bb0045","doi-asserted-by":"crossref","first-page":"8390","DOI":"10.1021\/acs.jmedchem.8b00913","article-title":"Discovery of indole derivatives as novel and potent dengue virus inhibitors","volume":"61","author":"Bardiot","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"14","key":"10.1016\/j.meegid.2026.106041_bb0050","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1016\/j.carres.2008.06.028","article-title":"Synthesis and antiviral activity of azoles obtained from carbohydrates","volume":"343","author":"Barradas","year":"2008","journal-title":"Carbohydrate Research"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"8","key":"10.1016\/j.meegid.2026.106041_bb0080","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrd.2017.33","article-title":"Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond","volume":"16","author":"Boldescu","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0085","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1038\/s41598-023-32049-x","article-title":"The 8-bromobaicalein inhibited the replication of dengue, and Zika viruses and targeted the dengue polymerase","volume":"13","author":"Boonyasuppayakorn","year":"2023","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.meegid.2026.106041_bb0090","first-page":"997","article-title":"Drug repurposing approaches to fight Dengue virus infection and related diseases","volume":"23","author":"Botta","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"10.1016\/j.meegid.2026.106041_bb0110","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1073\/pnas.0611681104","article-title":"c-Src protein kinase inhibitors block assembly and maturation of dengue virus","volume":"104","author":"Chu","year":"2007","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and immunogenicity of a tetravalent dengue DNA vaccine administered with a cationic lipid-based adjuvant in a phase 1 clinical trial","volume":"98","author":"Danko","year":"2018","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0130","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cell.2015.07.005","article-title":"Molecular insight into dengue virus pathogenesis and its implications for disease control","volume":"162","author":"Diamond","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.meegid.2026.106041_bb0135","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.4269\/ajtmh.17-0627","article-title":"Phase I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults from Puerto Rico","volume":"98","author":"Diaz","year":"2018","journal-title":"The American journal of tropical medicine and hygiene"},{"issue":"2","key":"10.1016\/j.meegid.2026.106041_bb0140","article-title":"Potential application of chitosan stabilized silver nanoparticles for simultaneous control of dengue virus and mosquito vectors","volume":"34","author":"Dung","year":"2022","journal-title":"Nanotechnology"},{"issue":"2","key":"10.1016\/j.meegid.2026.106041_bb0145","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4269\/ajtmh.20-0042","article-title":"Immunogenicity and safety of a tetravalent recombinant subunit dengue vaccine in adults previously vaccinated with a live attenuated tetravalent dengue vaccine: results of a phase-I randomized clinical trial","volume":"103","author":"Durbin","year":"2020","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"key":"10.1016\/j.meegid.2026.106041_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/mt.2016.43","article-title":"Progress with developing use of gene editing to cure chronic infection with hepatitis B virus","volume":"24","author":"Ely","year":"2016","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0155","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.celrep.2017.03.071","article-title":"The natural product cavinafungin selectively interferes with Zika and dengue virus replication by inhibition of the host signal peptidase","volume":"19","author":"Estoppey","year":"2017","journal-title":"Cell reports"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0160","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1038\/s41598-021-87707-9","article-title":"The antiviral effect of metformin on zika and dengue virus infection","volume":"11","author":"Farfan-Morales","year":"2021","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0165","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1097-2765(01)00206-4","article-title":"Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus","volume":"7","author":"Ferlenghi","year":"2001","journal-title":"Molecular cell"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0175","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41541-022-00537-2","article-title":"Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults","volume":"7","author":"Friberg","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.meegid.2026.106041_bb0180","doi-asserted-by":"crossref","first-page":"795","DOI":"10.52711\/0974-360X.2024.00123","article-title":"Identification of compounds from Zingiber officinale as Novel Inhibitor for Dengue DEN2 NS2B\/NS3 Serine Protease through Molecular Docking and DFT approaches","volume":"17","author":"Frimayanti","year":"2024","journal-title":"Res. J. Pharm. Technol"},{"issue":"2","key":"10.1016\/j.meegid.2026.106041_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006934","article-title":"Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes","volume":"14","author":"Gallichotte","year":"2018","journal-title":"PLoS pathogens"},{"issue":"7953","key":"10.1016\/j.meegid.2026.106041_bb0200","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41586-023-05790-6","article-title":"Blocking NS3\u2013NS4B interaction inhibits dengue virus in non-human primates","volume":"615","author":"Goethals","year":"2023","journal-title":"Nature"},{"issue":"33","key":"10.1016\/j.meegid.2026.106041_bb0210","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1016\/j.vaccine.2015.06.067","article-title":"Preclinical development of a dengue tetravalent recombinant subunit vaccine: immunogenicity and protective efficacy in nonhuman primates","volume":"33","author":"Govindarajan","year":"2015","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.meegid.2026.106041_bb0220","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.meegid.2026.106041_bb0225","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.3201\/eid0812.020170","article-title":"Dengue hemorrhagic fever in infants: research opportunities ignored","volume":"8","author":"Halstead","year":"2002","journal-title":"Emerging infectious diseases"},{"issue":"10","key":"10.1016\/j.meegid.2026.106041_bb0230","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(10)70166-3","article-title":"Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes","volume":"10","author":"Halstead","year":"2010","journal-title":"The Lancet infectious diseases"},{"key":"10.1016\/j.meegid.2026.106041_bb0240","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3389\/fmicb.2017.01674","article-title":"Hirsutine, an indole alkaloid of Uncaria rhynchophylla, inhibits late step in dengue virus lifecycle","volume":"8","author":"Hishiki","year":"2017","journal-title":"Frontiers in Microbiology"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0245","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41598-020-58468-8","article-title":"Evaluation of the antiviral activity of orlistat (tetrahydrolipstatin) against dengue virus, Japanese encephalitis virus, Zika virus and chikungunya virus","volume":"10","author":"Hitakarun","year":"2020","journal-title":"Scientific reports"},{"key":"10.1016\/j.meegid.2026.106041_bb0265","first-page":"1","article-title":"In Silico-Based Identification of Natural Inhibitors from Traditionally Used Medicinal Plants that can Inhibit Dengue Infection","author":"Islam","year":"2024","journal-title":"Molecular Biotechnology"},{"issue":"5","key":"10.1016\/j.meegid.2026.106041_bb0280","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2301790","article-title":"Live, attenuated, tetravalent Butantan\u2013Dengue vaccine in children and adults","volume":"390","author":"Kall\u00e1s","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.meegid.2026.106041_bb0275","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"The Lancet Infectious Diseases"},{"key":"10.1016\/j.meegid.2026.106041_bb0285","first-page":"10","article-title":"Dengue vaccines: Current status and future perspectives","author":"Kamath","year":"2024","journal-title":"APIK Journal of Internal Medicine"},{"issue":"7881","key":"10.1016\/j.meegid.2026.106041_bb0290","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","article-title":"A pan-serotype dengue virus inhibitor targeting the NS3\u2013NS4B interaction","volume":"598","author":"Kaptein","year":"2021","journal-title":"Nature"},{"issue":"6365","key":"10.1016\/j.meegid.2026.106041_bb0295","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0300","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nature reviews Drug discovery"},{"key":"10.1016\/j.meegid.2026.106041_bb0310","doi-asserted-by":"crossref","first-page":"11965","DOI":"10.1128\/JVI.01879-14","article-title":"Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR\/Cas RNA-guided endonuclease","volume":"88","author":"Kennedy","year":"2014","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0315","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/s41467-024-50437-3","article-title":"Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B\/NS3 and blocks replication organelle formation","volume":"15","author":"Kiemel","year":"2024","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0320","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1038\/s41598-024-61127-x","article-title":"Antiviral activity of pimecrolimus against dengue virus type 2 infection in vitro and in vivo","volume":"14","author":"Kim","year":"2024","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/CMR.00168-19","article-title":"Host-directed antiviral therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clinical microbiology reviews"},{"issue":"6","key":"10.1016\/j.meegid.2026.106041_bb0335","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jmii.2016.08.024","article-title":"Analyses of clinical and laboratory characteristics of dengue adults at their hospital presentations based on the World Health Organization clinical-phase framework: Emphasizing risk of severe dengue in the elderly","volume":"51","author":"Kuo","year":"2018","journal-title":"Journal of Microbiology, Immunology and Infection"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0345","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bmc.2012.10.058","article-title":"Design, synthesis and characterization of novel 1, 2-benzisothiazol-3 (2H)-one and 1, 3, 4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B\/NS3 proteases","volume":"21","author":"Lai","year":"2013","journal-title":"Bioorganic & medicinal chemistry"},{"key":"10.1016\/j.meegid.2026.106041_bb0350","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bcp.2017.01.005","article-title":"Pharmacological intervention for dengue virus infection","volume":"129","author":"Lai","year":"2017","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.meegid.2026.106041_bb0355","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2036.2010.04317.x","article-title":"Review article: specifically targeted anti-viral therapy for hepatitis C\u2014a new era in therapy","volume":"32","author":"Lange","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.meegid.2026.106041_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.01.002","article-title":"Characterization of the activity of 2\u2032-C-methylcytidine against dengue virus replication","volume":"116","author":"Lee","year":"2015","journal-title":"Antiviral research"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0365","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3390\/v15030705","article-title":"Molecular mechanisms of antiviral agents against dengue virus","volume":"15","author":"Lee","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2026.106041_bb0370","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3389\/fcimb.2017.00091","article-title":"Removal of integrated hepatitis B virus DNA using CRISPR-Cas9","volume":"7","author":"Li","year":"2017","journal-title":"Frontiers in cellular and infection microbiology"},{"key":"10.1016\/j.meegid.2026.106041_bb0375","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.omtn.2020.01.028","article-title":"CRISPR-Cas13a cleavage of dengue virus NS3 gene efficiently inhibits viral replication","volume":"19","author":"Li","year":"2020","journal-title":"Molecular Therapy-Nucleic Acids"},{"issue":"40","key":"10.1016\/j.meegid.2026.106041_bb0380","doi-asserted-by":"crossref","first-page":"2405829","DOI":"10.1002\/advs.202405829","article-title":"Discovery of Potent Degraders of the Dengue Virus Envelope Protein","volume":"11","author":"Li","year":"2024","journal-title":"Advanced Science"},{"issue":"10","key":"10.1016\/j.meegid.2026.106041_bb0395","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.3390\/biomedicines11102754","article-title":"The Antiviral Activity of Varenicline against Dengue Virus Replication during the Post-Entry Stage","volume":"11","author":"Lin","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0385","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4269\/ajtmh.19-0738","article-title":"Safety and immunogenicity of an AS03B-adjuvanted inactivated tetravalent dengue virus vaccine administered on varying schedules to healthy US adults: a phase 1\/2 randomized study","volume":"103","author":"Lin","year":"2020","journal-title":"The American journal of tropical medicine and hygiene"},{"key":"10.1016\/j.meegid.2026.106041_bb0400","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2016.12.031","article-title":"Two distant catalytic sites are responsible for C2c2 RNase activities","volume":"168","author":"Liu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.meegid.2026.106041_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104954","article-title":"Betulinic acid exhibits antiviral effects against dengue virus infection","volume":"184","author":"Loe","year":"2020","journal-title":"Antiviral research"},{"issue":"9","key":"10.1016\/j.meegid.2026.106041_bb0415","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: Results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Human vaccines & immunotherapeutics."},{"issue":"4","key":"10.1016\/j.meegid.2026.106041_bb0420","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000321892","article-title":"Statins reduce dengue virus production via decreased virion assembly","volume":"54","author":"Mart\u00ednez-Gutierrez","year":"2011","journal-title":"Intervirology"},{"key":"10.1016\/j.meegid.2026.106041_bb0425","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1016\/j.vaccine.2017.06.004","article-title":"ADE and dengue vaccination","volume":"35","author":"Mart\u00ednez-Vega","year":"2017","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.meegid.2026.106041_bb0430","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S2095-3119(19)62820-0","article-title":"Antiviral activity of traditional Chinese medicinal plants Dryopteris crassirhizoma and Morus alba against dengue virus","volume":"19","author":"Maryam","year":"2020","journal-title":"Journal of Integrative Agriculture"},{"issue":"22","key":"10.1016\/j.meegid.2026.106041_bb0440","doi-asserted-by":"crossref","first-page":"13911","DOI":"10.3390\/ijms232213911","article-title":"Engineering modified mRNA-based vaccine against dengue virus using computational and reverse vaccinology approaches","volume":"23","author":"Mukhtar","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0445","doi-asserted-by":"crossref","first-page":"85","DOI":"10.36348\/sjm.2023.v08i03.004","article-title":"In silico Evaluation of SNPs and Molecular Modelling Study in Dengue","volume":"8","author":"Murmu","year":"2023","journal-title":"Saudi J Med"},{"key":"10.1016\/j.meegid.2026.106041_bb0450","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00436-016-5310-0","article-title":"Magnetic nanoparticles are highly toxic to chloroquine-resistant Plasmodium falciparum, dengue virus (DEN-2), and their mosquito vectors","volume":"116","author":"Murugan","year":"2017","journal-title":"Parasitology research"},{"issue":"5","key":"10.1016\/j.meegid.2026.106041_bb0455","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.bmcl.2009.01.031","article-title":"A heterocyclic molecule with significant activity against dengue virus","volume":"19","author":"Nair","year":"2009","journal-title":"Bioorganic & medicinal chemistry letters"},{"issue":"10","key":"10.1016\/j.meegid.2026.106041_bb0460","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/v13101967","article-title":"Dengue virus infection: a tale of viral exploitations and host responses","volume":"13","author":"Nanaware","year":"2021","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.meegid.2026.106041_bb0465","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"The Journal of infectious diseases"},{"issue":"21","key":"10.1016\/j.meegid.2026.106041_bb0470","doi-asserted-by":"crossref","first-page":"8389","DOI":"10.1021\/jm400828u","article-title":"Thiazolidinone\u2013peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture","volume":"56","author":"Nitsche","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0475","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41467-021-21384-0","article-title":"A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans","volume":"12","author":"Nivarthi","year":"2021","journal-title":"Nature communications"},{"key":"10.1016\/j.meegid.2026.106041_bb0485","first-page":"1061937","article-title":"Assessing the potential of NS2B\/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs","volume":"13","author":"Norshidah","year":"2023","journal-title":"In vitro approach. Frontiers in cellular and infection microbiology"},{"key":"10.1016\/j.meegid.2026.106041_bb0490","series-title":"Anti-Viral Metabolites from Medicinal Plants","first-page":"683","article-title":"Herbal Drugs and Medicinal Plants in Controlling and Treatment of Diseases Caused by Dengue Virus (DEN-1 & 2): Ethnopharmacology, Chemistry, and Clinical and Preclinical Studies","author":"Pal","year":"2023"},{"issue":"10","key":"10.1016\/j.meegid.2026.106041_bb0495","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.3390\/molecules26103016","article-title":"In vitro antiviral activity of \u03b1-mangostin against dengue virus serotype-2 (DENV-2)","volume":"26","author":"Panda","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0515","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173328","article-title":"TV005 dengue vaccine protects against dengue serotypes 2 and 3 in two controlled human infection studies","volume":"134","author":"Pierce","year":"2024","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.meegid.2026.106041_bb0525","doi-asserted-by":"crossref","first-page":"105710","DOI":"10.1016\/j.meegid.2024.105710","article-title":"Dengue virus: Etiology, epidemiology, pathobiology, and developments in diagnosis and control\u2013A comprehensive review","volume":"127","author":"Pourzangiabadi","year":"2024","journal-title":"Infection, Genetics and Evolution"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0530","first-page":"178","article-title":"Dengue vaccine: Global development update","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.meegid.2026.106041_bb0535","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"Pu","year":"2018","journal-title":"Antiviral research"},{"issue":"10","key":"10.1016\/j.meegid.2026.106041_bb0540","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/v14102150","article-title":"A transcriptomics-based bioinformatics approach for identification and in vitro screening of FDA-approved drugs for repurposing against dengue virus-2","volume":"14","author":"Punekar","year":"2022","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.meegid.2026.106041_bb0545","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2174\/1389557520666200414162408","article-title":"Anti-DENV and anti-dengue vector activity of some heterocyclic scaffolds","volume":"20","author":"Purohit","year":"2020","journal-title":"Mini Reviews in Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.meegid.2026.106041_bb0550","doi-asserted-by":"crossref","DOI":"10.3390\/v14061226","article-title":"Mosquito-Borne Flaviviruses and Current Therapeutic Advances","volume":"14","author":"Qian","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.meegid.2026.106041_bb0555","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.actbio.2018.08.011","article-title":"Size-dependent neutralizing activity of gold nanoparticle-based subunit vaccine against dengue virus","volume":"78","author":"Quach","year":"2018","journal-title":"Acta biomaterialia"},{"key":"10.1016\/j.meegid.2026.106041_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41182-017-0072-7","article-title":"Identification of novel antiviral of fungus-derived brefeldin A against dengue viruses","volume":"45","author":"Raekiansyah","year":"2017","journal-title":"Tropical medicine and health"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006191","article-title":"A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice","volume":"12","author":"Ramasamy","year":"2018","journal-title":"PLoS neglected tropical diseases"},{"key":"10.1016\/j.meegid.2026.106041_bb0570","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3389\/fimmu.2019.01424","article-title":"A modified mRNA vaccine targeting immunodominant NS epitopes protects against dengue virus infection in HLA class I transgenic mice","volume":"10","author":"Roth","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"10.1016\/j.meegid.2026.106041_bb0575","doi-asserted-by":"crossref","DOI":"10.1002\/psc.3196","article-title":"Carnosine exhibits significant antiviral activity against Dengue and Zika virus","volume":"25","author":"Rothan","year":"2019","journal-title":"Journal of Peptide Science"},{"issue":"8","key":"10.1016\/j.meegid.2026.106041_bb0580","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/vaccines12080874","article-title":"Preclinical evaluation of novel sterically optimized VLP-based vaccines against all four DENV serotypes","volume":"12","author":"Rothen","year":"2024","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.meegid.2026.106041_bb0590","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.ymthe.2022.01.013","article-title":"Immune profile and responses of a novel dengue DNA vaccine encoding an EDIII-NS1 consensus design based on Indo-African sequences","volume":"30","author":"Sankaradoss","year":"2022","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0595","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/life11010016","article-title":"Nitrogen-based heterocyclic compounds: a promising class of antiviral agents against chikungunya virus","volume":"11","author":"Santana","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.meegid.2026.106041_bb0600","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejmech.2016.05.043","article-title":"Synthetic strategy and antiviral evaluation of diamide containing heterocycles targeting dengue and yellow fever virus","volume":"121","author":"Saudi","year":"2016","journal-title":"European journal of medicinal chemistry"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0605","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.celrep.2016.06.028","article-title":"Identification of Zika virus and dengue virus dependency factors using functional genomics","volume":"16","author":"Savidis","year":"2016","journal-title":"Cell reports"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0610","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/jvi.60.3.1153-1155.1986","article-title":"Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1","volume":"60","author":"Schlesinger","year":"1986","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0615","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-68-3-853","article-title":"Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1","volume":"68","author":"Schlesinger","year":"1987","journal-title":"Journal of General Virology"},{"issue":"7","key":"10.1016\/j.meegid.2026.106041_bb0625","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1089\/vim.2024.0032","article-title":"An Overview of the Types of Adjuvants Used in the Vaccination Industry And Their Mechanisms of Action","volume":"37","author":"Shams","year":"2024","journal-title":"Viral Immunology"},{"key":"10.1016\/j.meegid.2026.106041_bb0640","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.omtm.2021.04.014","article-title":"Potent programmable antiviral against dengue virus in primary human cells by Cas13b RNP with short spacer and delivery by VLP","volume":"21","author":"Singsuksawat","year":"2021","journal-title":"Molecular Therapy Methods & Clinical Development"},{"key":"10.1016\/j.meegid.2026.106041_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115416","article-title":"Perspectives on the current antiviral developments towards RNA-dependent RNA polymerase (RdRp) and methyltransferase (MTase) domains of dengue virus non-structural protein 5 (DENV-NS5)","volume":"256","author":"Sreekanth","year":"2023","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0690","doi-asserted-by":"crossref","first-page":"10397","DOI":"10.1038\/s41598-022-13923-6","article-title":"Studies on the antiviral activity of chebulinic acid against dengue and chikungunya viruses and in silico investigation of its mechanism of inhibition","volume":"12","author":"Thomas","year":"2022","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.meegid.2026.106041_bb0695","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00239-24","article-title":"A tetravalent dengue virus-like particle vaccine induces high levels of neutralizing antibodies and reduces dengue replication in non-human primates","volume":"98","author":"Thoresen","year":"2024","journal-title":"Journal of Virology"},{"issue":"3","key":"10.1016\/j.meegid.2026.106041_bb0700","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1248\/cpb.c17-00794","article-title":"Dengue virus and its inhibitors: a brief review","volume":"66","author":"Tian","year":"2018","journal-title":"Chemical and Pharmaceutical Bulletin"},{"issue":"2","key":"10.1016\/j.meegid.2026.106041_bb0710","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b7 5-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"The Lancet Global Health"},{"key":"10.1016\/j.meegid.2026.106041_bb0715","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.coviro.2020.07.009","article-title":"Recent advances in antiviral drug development towards dengue virus","volume":"43","author":"Troost","year":"2020","journal-title":"Current opinion in virology"},{"key":"10.1016\/j.meegid.2026.106041_bb0720","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3389\/fmicb.2017.00668","article-title":"Asunaprevir evokes hepatocytes innate immunity to restrict the replication of hepatitis C and dengue virus","volume":"8","author":"Tsai","year":"2017","journal-title":"Frontiers in Microbiology"},{"issue":"23","key":"10.1016\/j.meegid.2026.106041_bb0725","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.00556-18","article-title":"Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy for dengue vaccine","volume":"92","author":"Tsai","year":"2018","journal-title":"Journal of Virology"},{"issue":"23","key":"10.1016\/j.meegid.2026.106041_bb0730","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.01181-17","article-title":"An envelope-modified tetravalent dengue virus-like-particle vaccine has implications for flavivirus vaccine design","volume":"91","author":"Urakami","year":"2017","journal-title":"Journal of virology"},{"issue":"6","key":"10.1016\/j.meegid.2026.106041_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005701","article-title":"CRISPR\/Cas9-mediated genome editing of herpesviruses limits productive and latent infections","volume":"12","author":"Van Diemen","year":"2016","journal-title":"PLoS Pathogens"},{"key":"10.1016\/j.meegid.2026.106041_bb0745","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00705-018-3757-2","article-title":"Inhibition of dengue virus infection by small interfering RNAs that target highly conserved sequences in the NS4B or NS5 coding regions","volume":"163","author":"Villegas","year":"2018","journal-title":"Arch. Virol."},{"issue":"1","key":"10.1016\/j.meegid.2026.106041_bb0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004604","article-title":"Dengue virus RNA structure specialization facilitates host adaptation","volume":"11","author":"Villordo","year":"2015","journal-title":"PLoS pathogens"},{"issue":"2","key":"10.1016\/j.meegid.2026.106041_bb0755","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(23)00520-0","article-title":"Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial","volume":"24","author":"Walsh","year":"2024","journal-title":"The Lancet Infectious Diseases"},{"issue":"5","key":"10.1016\/j.meegid.2026.106041_bb0760","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41401-019-0316-7","article-title":"[1, 2, 4] Triazolo [1, 5-a] pyrimidine derivative (Mol-5) is a new NS5-RdRp inhibitor of DENV2 proliferation and DENV2-induced inflammation","volume":"41","author":"Wan","year":"2020","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.meegid.2026.106041_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112304","article-title":"Targets and strategies for vaccine development against dengue viruses","volume":"144","author":"Wang","year":"2021","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.meegid.2026.106041_bb0780","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1021\/acs.jmedchem.0c00067","article-title":"Targeting endoplasmic reticulum \u03b1-glucosidase I with a single-dose iminosugar treatment protects against lethal influenza and dengue virus infections","volume":"63","author":"Warfield","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"14","key":"10.1016\/j.meegid.2026.106041_bb0790","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1128\/JVI.79.14.8698-8706.2005","article-title":"Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo","volume":"79","author":"Whitby","year":"2005","journal-title":"Journal of virology"},{"issue":"35","key":"10.1016\/j.meegid.2026.106041_bb0795","first-page":"457","article-title":"Dengue vaccines: WHO position paper \u2013 September 2018","volume":"93","author":"WHO","year":"2018","journal-title":"Weekly Epidemiological Record"},{"key":"10.1016\/j.meegid.2026.106041_bb0805","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nature10886","article-title":"RNA-guided genetic silencing systems in bacteria and archaea","volume":"482","author":"Wiedenheft","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.meegid.2026.106041_bb0810","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.coviro.2020.09.004","article-title":"Dengue vaccine development by the year 2020: challenges and prospects","volume":"43","author":"Wilder-Smith","year":"2020","journal-title":"Current opinion in virology"},{"issue":"32","key":"10.1016\/j.meegid.2026.106041_bb0815","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1016\/j.vaccine.2019.06.083","article-title":"Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery","volume":"37","author":"Williams","year":"2019","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.meegid.2026.106041_bb0820","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JVI.02482-20","article-title":"A dengue virus serotype 1 mRNA-LNP vaccine elicits protective immune responses","volume":"95","author":"Wollner","year":"2021","journal-title":"Journal of Virology"},{"issue":"25-26","key":"10.1016\/j.meegid.2026.106041_bb0825","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1016\/S0264-410X(03)00310-4","article-title":"Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice","volume":"21","author":"Wu","year":"2003","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.meegid.2026.106041_bb0840","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taab146","article-title":"Global burden for dengue and the evolving pattern in the past 30 years","volume":"28","author":"Yang","year":"2021","journal-title":"Journal of travel medicine"},{"key":"10.1016\/j.meegid.2026.106041_bb0845","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.antiviral.2016.11.010","article-title":"Celastrol inhibits dengue virus replication via up-regulating type I interferon and downstream interferon-stimulated responses","volume":"137","author":"Yu","year":"2017","journal-title":"Antiviral research"},{"key":"10.1016\/j.meegid.2026.106041_bb0855","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP vaccines confer protection against experimental DENV-2 infection in mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Molecular therapy Methods & clinical development"},{"key":"10.1016\/j.meegid.2026.106041_bb0865","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-015-0150-z","article-title":"The CRISPR\/Cas9 system inactivates latent HIV-1 proviral DNA","volume":"12","author":"Zhu","year":"2015","journal-title":"Retrovirology"},{"issue":"22","key":"10.1016\/j.meegid.2026.106041_bb0870","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2217\/nnm-2022-0217","article-title":"Nanomedicine as a potential novel therapeutic approach against the dengue virus","volume":"18","author":"Zohra","year":"2023","journal-title":"Nanomedicine"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134826001656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134826001656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:35:36Z","timestamp":1794047736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134826001656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":122,"alternative-id":["S1567134826001656"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2026.106041","relation":{},"ISSN":["1567-1348"],"issn-type":[{"value":"1567-1348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of current technologies in the development of drugs and vaccines against dengue virus","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2026.106041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106041"}}